ARTICLE | Product Development
Building on Provenge
The next steps for cancer immunotherapy following Dendreon's Provenge
May 3, 2010 7:00 AM UTC
Last week's FDA approval of Provenge to treat metastatic prostate cancer has established immunotherapy as part of the cancer armamentarium. The question is what now will be done to build on what has been learned over the two decades it took to bring the first cancer vaccine to market in the U.S.
In fact, researchers have learned a great deal about how to stimulate the immune system to attack tumor antigens and prevent cancer cells from evading immune surveillance...